Abstract |
Despite great efforts and resources being devoted to treatment, the incidence and mortality of numerous cancers have not decreased in recent decades. This is a result of the resistance of cancer cells to chemotherapeutic agents and radio- therapy. The development of antiangiogenic agents that target vascular endothelial growth factor ( VEGF) provides a new option for treatment of cancer. Major advances have been achieved with cancer therapy based on antiangiogenic VEGF-targeted agents in the past few years, and some of the recently approved therapies are now being used in daily clinical practice. A further challenge is finding a more efficacious combination of antiangiogenic VEGF-targeted therapies and conventional radio- and chemotherapies. This review outlines the current preclinical and clinical cancer treatments using optimized combinations of antiangiogenic VEGF-targeted agents and conventional radiochemotherapy and highlights that better scheduling for the combination of radiochemotherapy and antiangiogenic VEGF-targeted agents should be developed to achieve better treatment outcomes.
|
Authors | Li-Song Teng, Ke-Tao Jin, Kui-Feng He, Hao-Hao Wang, Jiang Cao, De-Cao Yu |
Journal | Journal of the Chinese Medical Association : JCMA
(J Chin Med Assoc)
Vol. 73
Issue 6
Pg. 281-8
(Jun 2010)
ISSN: 1728-7731 [Electronic] Netherlands |
PMID | 20603084
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright (c) 2010 Elsevier. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Angiogenesis Inhibitors
- Vascular Endothelial Growth Factor A
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Combined Modality Therapy
- Humans
- Neoplasms
(blood supply, therapy)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
|